mTOR inhibitors are currently in clinical trials for treating RCC [9–13], and our previous studies showed that in colon and lung cancer cells expressing wild-type p53, NR4A1 inhibits p53 activity and p53-dependent inhibition of the mTOR pathway [15]. This evidence concerns the gene TP53 and renal cell adenocarcinoma.